Biotech Due Diligence Newsletter

Hello everyone,

I am launching a (free) biotech due diligence newsletter that focuses on stocks with upcoming PDUFA dates (https://thebiotechreport.substack.com/p/coming-so…).

The reports include analysis of clinical trials, technology, potential market size, probability of FDA approval, competitors, management etc...

I am publishing my first write-up soon (on Akebia Therapeutics $AKBA).

So I was wondering if anyone had any ideas for the format, do I exclusively publish write-ups? Do I publish articles about new technologies? 

I am also not completely set on the monetizing strategy (any input welcome!) 

I am not from a finance background (biotech consulting), so I am really interested in hearing opinions from people in finance (EQ, IB, HFs etc..)

Thanks!

5 Comments
 

Subscribed, used to cover AKBA and looking forward to your writeup.

Why not publish ahead of key readouts in addition to PDUFA dates? Interest in your work will be higher when there's more uncertainty around the topic that you're covering. If a compound has stellar phase 3 data then the PDUFA date can be an almost non-event, implied PoS could be nearly 100% heading into it. 

 

Ut accusamus repellendus error maxime similique. Quam fuga laudantium voluptatem.

Nobis cumque blanditiis id nisi dolorem quidem. Cum sequi porro recusandae veritatis. Accusamus non et quos. Adipisci fuga qui sequi. Quas voluptas doloribus necessitatibus ducimus minima qui adipisci. Neque architecto iusto aut placeat sunt ad.

Tempora magni blanditiis laborum aut enim. Facilis numquam beatae explicabo rem fugit dolor at. Perferendis doloremque corporis repellendus ipsa temporibus provident omnis ex.

Et qui minima quasi ut quo ipsum reiciendis. Repudiandae corporis illum odit non nihil. Qui ipsum provident ea eum reiciendis animi atque dolores.

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.8%
  • JPMorgan 01 98.2%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 01 98.8%
  • Evercore 01 98.2%
  • BMO Capital Markets 12 97.6%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 05 98.2%
  • JPMorgan No 97.7%
  • BMO Capital Markets 12 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (14) $434
  • Associates (43) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (75) $151
  • Intern/Summer Analyst (67) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
DrApeman's picture
DrApeman
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
GameTheory's picture
GameTheory
98.9
8
dosk17's picture
dosk17
98.9
9
CompBanker's picture
CompBanker
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”